Another potential PDAC-related biomarker of liver metastases is the CD44v6/C1QBP complex carried by HSC exosomes: higher levels in patients than in healthy people were found, and it appears to be involved in the activation of the IGF-1 signaling pathway, essential for PDAC progression, invasion, and chemoresistance, leading the authors to suggest that highly expressed EXOs associated with CD44v6 and C1QBP are promising biomarkers for predicting prognosis and liver metastasis in patients with this tumor [142]. The gene discussed is C1QBP; the disease is neoplasm.